News

Back

TheraVet completes first regulatory milestones for the US registration (NADA) of VISCO-VET in canine osteoarthritis

June 15th 2020

BioPark

TheraVet S.A., the specialist of the osteo-articular diseases in small companion animals, announces today passing the first regulatory milestones for its product VISCO-VET in the indication of canine osteoarthritis with the U.S. Food & Drug Administration's (FDA) Center for Veterinary Medicine (CVM). Please discover the press release here.